Cargando…

NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition

Although histone deacetylase 8 (HDAC8) plays a role in glioblastoma multiforme (GBM), whether its inhibition facilitates the treatment of temozolomide (TMZ)-resistant GBM (GBM-R) remains unclear. By assessing the gene expression profiles from short hairpin RNA of HDAC8 in the new version of Connecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsai, Cheng-Yu, Ko, Huey-Jiun, Chiou, Shean-Jaw, Lai, Yu-Ling, Hou, Chia-Chung, Javaria, Tehseen, Huang, Zi-Yi, Cheng, Tai-Shan, Hsu, Tsung-I, Chuang, Jian-Ying, Kwan, Aij-Lie, Chuang, Tsung-Hsien, Huang, Chi-Ying F., Loh, Joon-Khim, Hong, Yi-Ren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199487/ https://www.ncbi.nlm.nih.gov/pubmed/34072831 http://dx.doi.org/10.3390/ijms22115907

Ejemplares similares

BMX, a specific HDAC8 inhibitor, with TMZ for advanced CRC therapy: a novel synergic effect to elicit p53-, β-catenin- and MGMT-dependent apoptotic cell death
por: Ko, Huey-Jiun, et al.
Publicado: (2022)

Anti-Cancer Activity of an Osthole Derivative, NBM-T-BMX-OS01: Targeting Vascular Endothelial Growth Factor Receptor Signaling and Angiogenesis
por: Yang, Hung-Yu, et al.
Publicado: (2013)

NBM-T-L-BMX-OS01, Semisynthesized from Osthole, Is a Novel Inhibitor of Histone Deacetylase and Enhances Learning and Memory in Rats
por: Yang, Ying-Chen, et al.
Publicado: (2013)

The Phosphorylation Status of Drp1-Ser637 by PKA in Mitochondrial Fission Modulates Mitophagy via PINK1/Parkin to Exert Multipolar Spindles Assembly during Mitosis
por: Ko, Huey-Jiun, et al.
Publicado: (2021)

Ionizing Radiation Induces Resistant Glioblastoma Stem-Like Cells by Promoting Autophagy via the Wnt/β-Catenin Pathway
por: Tsai, Cheng-Yu, et al.
Publicado: (2021)

GSKIP modulates cell aggregation through EMT/MET signaling rather than differentiation in SH-SY5Y human neuroblastoma cells
por: Tsai, Cheng-Yu, et al.
Publicado: (2023)

NBM-HD-1: A Novel Histone Deacetylase Inhibitor with Anticancer Activity
por: Huang, Wei-Jan, et al.
Publicado: (2012)

Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells
por: Qiu, Zhi-Kun, et al.
Publicado: (2014)

Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression
por: Gao, Yong-tao, et al.
Publicado: (2016)

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
por: van Nifterik, K A, et al.
Publicado: (2010)

Deciphering the evolution of composite-type GSKIP in mitochondria and Wnt signaling pathways
por: Tsai, Cheng-Yu, et al.
Publicado: (2022)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
por: Thomas, Reena P, et al.
Publicado: (2012)

A molecular dynamics simulation study decodes the Zika virus NS5 methyltransferase bound to SAH and RNA analogue
por: Chuang, Chih-Hung, et al.
Publicado: (2018)

The Role of miRNA for the Treatment of MGMT Unmethylated Glioblastoma Multiforme
por: Kirstein, Anna, et al.
Publicado: (2020)

Use Of Temozolomide In Parathyroid Carcinoma With Negative Mgmt Promoter Methylation
por: Reddy, Niyoti, et al.
Publicado: (2021)

Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival
por: Rahman, Mohummad Aminur, et al.
Publicado: (2019)

BMX: Biological modelling and interface exchange
por: Palmer, Bruce J., et al.
Publicado: (2023)

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas
por: ABE, Hideaki, et al.
Publicado: (2018)

The Double-Edged Sword of Beta2-Microglobulin in Antibacterial Properties and Amyloid Fibril-Mediated Cytotoxicity
por: Chiou, Shean-Jaw, et al.
Publicado: (2021)

Suppressing TRAP1 sensitizes glioblastoma multiforme cells to temozolomide
por: Wang, Nan, et al.
Publicado: (2021)

Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy
por: Wang, Nan, et al.
Publicado: (2021)

Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2
por: Yi, Guo-zhong, et al.
Publicado: (2019)

Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
por: Faye, Mame Daro, et al.
Publicado: (2023)

Regulation of temozolomide resistance in glioma cells via the RIP2/NF‐κB/MGMT pathway
por: Hu, Yu‐Hua, et al.
Publicado: (2021)

Exploring the Functional Roles of Telomere Maintenance 2 in the Tumorigenesis of Glioblastoma Multiforme and Drug Responsiveness to Temozolomide
por: Feng, Shao-Wei, et al.
Publicado: (2023)

Lomeguatrib Increases the Radiosensitivity of MGMT Unmethylated Human Glioblastoma Multiforme Cell Lines
por: Kirstein, Anna, et al.
Publicado: (2021)

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy
por: Dunn, J, et al.
Publicado: (2009)

Valproic Acid Downregulates the Expression of MGMT and Sensitizes Temozolomide-Resistant Glioma Cells
por: Ryu, Chung Heon, et al.
Publicado: (2012)

A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
por: Chen, Xiaoyue, et al.
Publicado: (2018)

The Impact of MGMT Promoter Methylation and Temozolomide Treatment in Serbian Patients with Primary Glioblastoma
por: Jovanović, Nikola, et al.
Publicado: (2019)

The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma
por: Xu, Haoyue, et al.
Publicado: (2022)

Elimination of Cancer Stem-Like Cells and Potentiation of Temozolomide Sensitivity by Honokiol in Glioblastoma Multiforme Cells
por: Lai, I-Chun, et al.
Publicado: (2015)

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
por: Melguizo, Consolación, et al.
Publicado: (2012)

NBM-T-BBX-OS01, Semisynthesized from Osthole, Induced G1 Growth Arrest through HDAC6 Inhibition in Lung Cancer Cells
por: Pai, Jih-Tung, et al.
Publicado: (2015)

The expression and role of tyrosine kinase ETK/BMX in renal cell carcinoma
por: Zhuang, Jintao, et al.
Publicado: (2014)

Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
por: Castro, Michael, et al.
Publicado: (2021)

MGMT and Whole-Genome DNA Methylation Impacts on Diagnosis, Prognosis and Therapy of Glioblastoma Multiforme
por: Della Monica, Rosa, et al.
Publicado: (2022)

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome
por: Hassel, J C, et al.
Publicado: (2010)

Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital
por: Egaña, Larraitz, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ththcnjpp1b2dnr2lglrf6h6og